Colangelo Dominick 4

What Happened
Dominick Colangelo, a director of Trevi Therapeutics, was granted a derivative award on June 3, 2026: an option covering 35,000 shares with an acquisition price of $0. The reported acquisition value is $0 because this was an awarded derivative security (not an open‑market purchase or sale). This is a grant of compensation, not an immediate cash investment or sale.

Key Details

• Transaction date: 2026-06-03; Form 4 filed: 2026-06-04 (timely filing).
• Security: derivative award (option) for 35,000 shares; price reported $0.00.
• Vesting: option is scheduled to fully vest on the earlier of (i) the first anniversary of the grant or (ii) the next annual meeting of stockholders, subject to continued service.
• Shares owned after transaction: not specified in the provided filing excerpt.
• No 10b5-1 plan, cashless exercise, tax‑withholding, or sale noted in this filing.

Context
Derivative grants to directors are common as compensation for service; because this award vests over time and is contingent on continued service, it may be forfeited if Colangelo leaves before vesting. Such awards are informational rather than direct market endorsements — they don’t indicate an immediate buy or sell by the insider.